(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 August 2010 (26.08.2010)

PCT

(10) International Publication Number
WO 2010/094723 A3

(51) International Patent Classification:
C07K 16/18 (2006.01) *C07K 14/56* (2006.01)
C07K 16/28 (2006.01) *C07K 14/575* (2006.01)

(21) International Application Number:
PCT/EP2010/052008

(22) International Filing Date:
17 February 2010 (17.02.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/153,746 19 February 2009 (19.02.2009) US
61/163,987 27 March 2009 (27.03.2009) US
61/247,136 30 September 2009 (30.09.2009) US

(71) Applicant *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DE ANGELIS, Elena** [GB/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge, Cambridgeshire CB4 0WG (GB). **ENEVER, Carolyn** [GB/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge, Cambridgeshire CB4 0WG (GB). **LIU, Haiqun** [CN/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge, Cambridgeshire CB4 0WG (GB). **PLUMMER, Christopher** [GB/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge, Cambridgeshire CB4 0WG (GB). **SCHON, Oliver** [DE/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge, Cambridgeshire CB4 0WG (GB).

(74) Agents: **CLUBE, Jasper, Rupert** et al.; GlaxoSmithKline, Global Patents CN925.1, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
21 April 2011

(54) Title: IMPROVED ANTI-SERUM ALBUMIN BINDING VARIANTS

(57) Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.

WO 2010/094723 A3